Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 3
1985 2
1986 19
1987 9
1988 5
1989 4
1990 13
1991 9
1992 11
1993 10
1994 11
1995 17
1996 8
1997 12
1998 11
1999 13
2000 14
2001 14
2002 13
2003 14
2004 13
2005 12
2006 17
2007 20
2008 15
2009 20
2010 15
2011 15
2012 19
2013 20
2014 10
2015 21
2016 13
2017 15
2018 11
2019 8
2020 13
2021 13
2022 9
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

454 results
Results by year
Filters applied: . Clear all
Page 1
Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial.
Kotecha D, Bunting KV, Gill SK, Mehta S, Stanbury M, Jones JC, Haynes S, Calvert MJ, Deeks JJ, Steeds RP, Strauss VY, Rahimi K, Camm AJ, Griffith M, Lip GYH, Townend JN, Kirchhof P; Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF) Team. Kotecha D, et al. JAMA. 2020 Dec 22;324(24):2497-2508. doi: 10.1001/jama.2020.23138. JAMA. 2020. PMID: 33351042 Free PMC article. Clinical Trial.
INTERVENTIONS: Digoxin (n = 80; dose range, 62.5-250 mug/d; mean dose, 161 mug/d) or bisoprolol (n = 80; dose range, 1.25-15 mg/d; mean dose, 3.2 mg/d). ...Adverse events were less common with digoxin; 20 patients (25%) in the digoxin group had at least 1 AE vs 51 patients …
INTERVENTIONS: Digoxin (n = 80; dose range, 62.5-250 mug/d; mean dose, 161 mug/d) or bisoprolol (n = 80; dose range, 1.25-15 mg/d; me …
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
[No authors listed] [No authors listed] Lancet. 1999 Jan 2;353(9146):9-13. Lancet. 1999. PMID: 10023943 Clinical Trial.
FINDINGS: CIBIS-II was stopped early, after the second interim analysis, because bisoprolol showed a significant mortality benefit. All-cause mortality was significantly lower with bisoprolol than on placebo (156 [11.8%] vs 228 [17.3%] deaths with a hazard ratio of …
FINDINGS: CIBIS-II was stopped early, after the second interim analysis, because bisoprolol showed a significant mortality benefit. A …
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.
Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford I, Cruickshank JK, Caulfield MJ, Salsbury J, Mackenzie I, Padmanabhan S, Brown MJ; British Hypertension Society's PATHWAY Studies Group. Williams B, et al. Lancet. 2015 Nov 21;386(10008):2059-2068. doi: 10.1016/S0140-6736(15)00257-3. Epub 2015 Sep 20. Lancet. 2015. PMID: 26414968 Free PMC article. Clinical Trial.
After 21 were excluded, 285 patients received spironolactone, 282 doxazosin, 285 bisoprolol, and 274 placebo; 230 patients completed all treatment cycles. The average reduction in home systolic blood pressure by spironolactone was superior to placebo (-8.70 mm Hg [95% CI - …
After 21 were excluded, 285 patients received spironolactone, 282 doxazosin, 285 bisoprolol, and 274 placebo; 230 patients completed …
Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial.
Chow CK, Atkins ER, Hillis GS, Nelson MR, Reid CM, Schlaich MP, Hay P, Rogers K, Billot L, Burke M, Chalmers J, Neal B, Patel A, Usherwood T, Webster R, Rodgers A; QUARTET Investigators. Chow CK, et al. Lancet. 2021 Sep 18;398(10305):1043-1052. doi: 10.1016/S0140-6736(21)01922-X. Epub 2021 Aug 29. Lancet. 2021. PMID: 34469767 Clinical Trial.
Participants were randomly assigned to either treatment, that started with the quadpill (containing irbesartan at 37.5 mg, amlodipine at 1.25 mg, indapamide at 0.625 mg, and bisoprolol at 2.5 mg) or an indistinguishable monotherapy control (irbesartan 150 mg). ...
Participants were randomly assigned to either treatment, that started with the quadpill (containing irbesartan at 37.5 mg, amlodipine at 1.2 …
Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS).
Cotton S, Devereux G, Abbas H, Briggs A, Campbell K, Chaudhuri R, Choudhury G, Dawson D, De Soyza A, Fielding S, Gompertz S, Haughney J, Lang CC, Lee AJ, MacLennan G, MacNee W, McCormack K, McMeekin N, Mills NL, Morice A, Norrie J, Petrie MC, Price D, Short P, Vestbo J, Walker P, Wedzicha J, Wilson A, Lipworth BJ. Cotton S, et al. Trials. 2022 Apr 14;23(1):307. doi: 10.1186/s13063-022-06226-8. Trials. 2022. PMID: 35422024 Free PMC article. Clinical Trial.
Observational studies consistently report that beta blocker use in people with COPD is associated with a reduced risk of COPD exacerbations. The bisoprolol in COPD study (BICS) investigates whether adding bisoprolol to routine COPD treatment has clinical and cost-ef …
Observational studies consistently report that beta blocker use in people with COPD is associated with a reduced risk of COPD exacerbations. …
Tolerability, Efficacy, and Safety of Bisoprolol vs. Carvedilol in Japanese Patients With Heart Failure and Reduced Ejection Fraction　- The CIBIS-J Trial.
Tsutsui H, Momomura SI, Masuyama T, Saito Y, Komuro I, Murohara T, Kinugawa S; CIBIS-J Investigators. Tsutsui H, et al. Circ J. 2019 May 24;83(6):1269-1277. doi: 10.1253/circj.CJ-18-1199. Epub 2019 Apr 6. Circ J. 2019. PMID: 30956267 Free article. Clinical Trial.
The primary endpoint was achieved in 41.4% of patients in bisoprolol (n=111) and 42.5% in carvedilol (n=106) groups. The non-inferiority of tolerability of bisoprolol compared with carvedilol was not supported, however, neither beta-blocker was superior with regard …
The primary endpoint was achieved in 41.4% of patients in bisoprolol (n=111) and 42.5% in carvedilol (n=106) groups. The non-inferior …
Cardioprotective Strategy for Patients With Nonmetastatic Breast Cancer Who Are Receiving an Anthracycline-Based Chemotherapy: A Randomized Clinical Trial.
Livi L, Barletta G, Martella F, Saieva C, Desideri I, Bacci C, Del Bene MR, Airoldi M, Amoroso D, Coltelli L, Scotti V, Becherini C, Visani L, Salvestrini V, Mariotti M, Pedani F, Bernini M, Sanchez L, Orzalesi L, Nori J, Bianchi S, Olivotto I, Meattini I. Livi L, et al. JAMA Oncol. 2021 Oct 1;7(10):1544-1549. doi: 10.1001/jamaoncol.2021.3395. JAMA Oncol. 2021. PMID: 34436523 Free PMC article. Clinical Trial.
At 12 months, 3D-LVEF worsened by 4.4% in placebo arm and 3.0%, 1.9%, 1.3% in the ramipril, bisoprolol, ramipril plus bisoprolol arms, respectively (P = .01). Global longitudinal strain worsened by 6.0% in placebo arm and 1.5% and 0.6% in the ramipril and bisopro …
At 12 months, 3D-LVEF worsened by 4.4% in placebo arm and 3.0%, 1.9%, 1.3% in the ramipril, bisoprolol, ramipril plus bisoprolol …
Effects of carvedilol vs bisoprolol on inflammation and oxidative stress in patients with chronic heart failure.
Toyoda S, Haruyama A, Inami S, Arikawa T, Saito F, Watanabe R, Sakuma M, Abe S, Nakajima T, Tanaka A, Node K, Inoue T. Toyoda S, et al. J Cardiol. 2020 Feb;75(2):140-147. doi: 10.1016/j.jjcc.2019.07.011. Epub 2019 Aug 21. J Cardiol. 2020. PMID: 31444140 Free article. Clinical Trial.
In all 48 patients, the change in hsTnT was correlated with that in hsCRP (R = 0.467, p = 0.003). CONCLUSIONS: Bisoprolol may be better than carvedilol for reducing inflammation, but carvedilol may be better than bisoprolol for reducing oxidative stress. Proper use …
In all 48 patients, the change in hsTnT was correlated with that in hsCRP (R = 0.467, p = 0.003). CONCLUSIONS: Bisoprolol may be bett …
A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees.
[No authors listed] [No authors listed] Circulation. 1994 Oct;90(4):1765-73. doi: 10.1161/01.cir.90.4.1765. Circulation. 1994. PMID: 7923660 Clinical Trial.
No significant difference was observed in sudden death rate (17 on placebo, 15 on bisoprolol) or death related to documented ventricular tachycardia or fibrillation (7 on placebo, 4 on bisoprolol). Bisoprolol significantly improved the functional status of th …
No significant difference was observed in sudden death rate (17 on placebo, 15 on bisoprolol) or death related to documented ventricu …
Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use: a Danish nationwide cohort study.
Sessa M, Mascolo A, Mortensen RN, Andersen MP, Rosano GMC, Capuano A, Rossi F, Gislason G, Enghusen-Poulsen H, Torp-Pedersen C. Sessa M, et al. Eur J Heart Fail. 2018 Mar;20(3):548-556. doi: 10.1002/ejhf.1045. Epub 2017 Nov 20. Eur J Heart Fail. 2018. PMID: 29159953 Free article. Clinical Trial.
Carvedilol users had a higher hazard of being hospitalized for HF compared with metoprolol/bisoprolol/nebivolol users in both the unadjusted [hazard ratio (HR) 1.74; 95% confidence interval (CI) 1.65-1.83] and adjusted (HR 1.61; 95% CI 1.52-1.70) analyses. ...Carvedilol us …
Carvedilol users had a higher hazard of being hospitalized for HF compared with metoprolol/bisoprolol/nebivolol users in both the una …
454 results